Pubblicazioni

Autori:

Palandri, Francesca; Palumbo, Giuseppe A; Benevolo, Giulia; Iurlo, Alessandra; Elli, Elena M; Abruzzese, Elisabetta; Polverelli, Nicola; Tiribelli, Mario; Auteri, Giuseppe; Tieghi, Alessia; Caocci, Giovanni; Binotto, Gianni; Cavazzini, Francesco; Branzanti, Filippo; Beggiato, Eloise; Miglino, Maurizio; Bosi, Costanza; Crugnola, Monica; Bocchia, Monica; Martino, Bruno; Pugliese, Novella; Scaffidi, Luigi; Venturi, Marta; Duminuco, Andrea; Isidori, Alessandro; Cattaneo, Daniele; Krampera, Mauro; Pane, Fabrizio; Cilloni, Daniela; Semenzato, Gianpietro; Lemoli, Roberto M; Cuneo, Antonio; Trawinska, Malgorzata M; Vianelli, Nicola; Cavo, Michele; Bonifacio, Massimiliano; Breccia, Massimo

Titolo:

Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy

Anno:

2024

Tipologia prodotto:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Lingua:

Inglese

Referee:

No

Nome rivista:

Cancer

ISSN Rivista:

0008-543X

N° Volume:

130

Numero o Fascicolo:

8

Intervallo pagine:

1270-1280

Parole chiave:

anemia; blast phase; myelofibrosis; ruxolitinib

Breve descrizione dei contenuti:

Background: Anemia is frequently present in patients with myelofibrosis (MF), and it may be exacerbated by treatment with the JAK2-inhibitor ruxolitinib (RUX). Recently, a relevant blast phase (BP) incidence has been reported in anemic MF patients unexposed to RUX.Methods: The authors investigated the incidence of BP in 886 RUX-treated MF patients, included in the "RUX-MF" retrospective study.Results: The BP incidence rate ratio (IRR) was 3.74 per 100 patient-years (3.74 %p-y). At therapy start, Common Terminology Criteria for Adverse Events grade 3-4 anemia (hemoglobin [Hb] <8 g/dL) and severe sex/severity-adjusted anemia (Hb <8/<9 g/dL in women/men) were present in 22.5% and 25% patients, respectively. IRR of BP was 2.34 in patients with no baseline anemia and reached respectively 4.22, 4.89, and 4.93 %p-y in patients with grade 1, 2, and 3-4 anemia. Considering the sex/severity-adjusted Hb thresholds, IRR of BP was 2.85, 4.97, and 4.89 %p-y in patients with mild/no anemia, moderate, and severe anemia. Transfusion-dependent patients had the highest IRR (5.03 %p-y). Progression-free survival at 5 years was 70%, 52%, 43%, and 27% in patients with no, grade 1, 2, and 3-4 anemia, respectively (p < .001). At 6 months, 260 of 289 patients with no baseline anemia were receiving ruxolitinib, and 9.2% had developed a grade 3-4 anemia. By 6-month landmark analysis, BP-free survival was significantly worse in patients acquiring grade 3-4 anemia (69.3% vs. 88.1% at 5 years, p < .001).Conclusions: This study highlights that anemia correlates with an increased risk of evolution into BP, both when present at baseline and when acquired during RUX monotherapy. Innovative anemia therapies and disease-modifying agents are warranted in these patients.

Id prodotto:

139548

Handle IRIS:

11562/1126172

ultima modifica:

30 ottobre 2024

Citazione bibliografica:

Palandri, Francesca; Palumbo, Giuseppe A; Benevolo, Giulia; Iurlo, Alessandra; Elli, Elena M; Abruzzese, Elisabetta; Polverelli, Nicola; Tiribelli, Mario; Auteri, Giuseppe; Tieghi, Alessia; Caocci, Giovanni; Binotto, Gianni; Cavazzini, Francesco; Branzanti, Filippo; Beggiato, Eloise; Miglino, Maurizio; Bosi, Costanza; Crugnola, Monica; Bocchia, Monica; Martino, Bruno; Pugliese, Novella; Scaffidi, Luigi; Venturi, Marta; Duminuco, Andrea; Isidori, Alessandro; Cattaneo, Daniele; Krampera, Mauro; Pane, Fabrizio; Cilloni, Daniela; Semenzato, Gianpietro; Lemoli, Roberto M; Cuneo, Antonio; Trawinska, Malgorzata M; Vianelli, Nicola; Cavo, Michele; Bonifacio, Massimiliano; Breccia, Massimo, Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy «Cancer» , vol. 130 , n. 8 , 2024 , pp. 1270-1280

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo